Related Experiment Video
Updated: May 7, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children
Michael D Deel1, Maiying Kong, Keith P Cross
1Department of Pediatrics, School of Medicine, University of Louisville, Louisville, Kentucky; Norton's Kosair Children's Hospital, Louisville, Kentucky.
Insights
Lowering absolute lymphocyte counts (ALCs) within three months can predict chronic immune thrombocytopenia (ITP). This finding aids in stratifying patients with ITP for better management and treatment strategies.
Area of Science:
- Hematology
- Immunology
- Clinical Medicine
Background:
- Immune thrombocytopenia (ITP) may involve distinct acute and chronic immunopathological mechanisms.
- Evaluating absolute lymphocyte counts (ALCs) as potential predictors for ITP outcomes is crucial.
Purpose of the Study:
- To assess the predictive value of ALCs for immune thrombocytopenia (ITP) progression and outcomes.
- To determine if ALC levels at specific time points correlate with the development of chronic ITP.
Main Methods:
- Collected complete blood counts (CBCs) with differential counts for 204 ITP patients at presentation and at 3, 6, and 12 months.
- Utilized receiver operating characteristic (ROC) curves to establish cutoff values for ALCs.
- Employed logistic regression and recursive partitioning to identify significant predictors of ITP outcomes.
Main Results:
- ALC values at presentation did not independently predict disease duration.
- ALC values at 3 months post-presentation were significant predictors of chronic ITP.
- Patients with a 3-month ALC ≤ 3,000/μl had significantly higher rates of developing chronic ITP compared to those with ALC > 3,000/μl.
Conclusions:
- A decline in lymphocyte counts within the first few months is a strong predictor of chronic ITP.
- ALC measurements at 3 months allow for risk stratification of ITP patients.
- Further research is warranted to confirm these findings and explore underlying pathophysiological mechanisms.
Background:
Recent studies reviewing immune mechanisms of immune thrombocytopenia (ITP) have suggested acute and chronic forms may represent distinct immunopathological disorders. This study evaluated absolute lymphocyte counts (ALCs) as predictors for ITP outcomes.
Procedure:
CBCs with differential counts were ascertained at presentation, 3, 6, and 12 months for 204 patients. Receiver operating characteristic (ROC) curves were used to determine cutoff values. Logistic regression models and recursive partitioning were used to evaluate which variables were significantly associated with outcomes.
Results:
ALC values at presentation were not independently predictive of disease duration. However, ALC values at 3 months were significant predictors. Sixty-eight percent (40/59) of patients >8 years of age and 43% (20/46) of patients ≤ 8 years who had an ALC ≤ 3,000/μl at 3 months developed chronic ITP. This compares to chronic rates of only 25% (3/12) and 2% (2/87) of patients >8 and ≤ 8 years, respectively, with an ALC > 3,000/μl at 3 months. Further, 92% (60/65) of patients who developed chronic ITP had a 3-month ALC ≤ 3,000/μl. An ALC > 3,000/μl at 3 months is a strong predictor for platelet recovery as only 5% (5/99) of these patients developed chronic ITP.
Conclusion:
This study suggests progression to lower lymphocyte counts over the first few months of disease is a strong predictor for chronic ITP, allowing for risk stratification of patients, particularly when used in conjunction with other known predictors. Further research is needed to confirm these findings and to fully investigate the pathophysiological mechanisms responsible for this association.
More Related Videos
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018